Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCCS: Adjuvant RadioChemotherapy Concurrent versus Sequential in Resected NSCLC pN2
2019-000364-24Phase 2Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in non-small cell lung cancer (NSCLC) and lung neoplasm (2 arms), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Locoregional relapse-free survival. Started May 2021; status: completed.
02
Drugs
cisplatin
03
Conditions
non-small cell lung cancer (NSCLC)lung neoplasm
Beyond the preview
Go deeper on 2019-000364-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000364-24.